1. Scrip
  2. >>Drug Pricing

Industry Looks At IRA Drawbacks And Silver Linings

Drug Pricing Changes Were Top Of Mind At J.P. Morgan

 
• By Jessica Merrill

Industry leaders are concerned about the outlook for small molecule drugs in particular, but execs at the J.P. Morgan Healthcare Conference were also optimistic there could be chances to shape the implementation of certain policies.

two couple are showing half full and half empty side of water glass with their fingers
Industry Looking For Upsides From The IRA

One of the biopharma industry’s biggest worries has been how the Inflation Reduction Act (IRA) will impact US drug pricing and consequently innovation over the long term. So it was expected to be a key topic for one of the industry’s biggest meetings, the J.P. Morgan Healthcare Conference. But while the lack of specifics kept discussion limited during the main stage presentations, executives interviewed by Scrip offered a range of expectations.

Industry leaders have been afraid policies that will allow the US government to negotiate drug prices will have a dire...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Drug Pricing

Lilly Begins Rebalancing US/Ex-US Drug Costs By Raising Prices In Europe

 
• By Mandy Jackson

Lilly said prices governments pay in developed countries, including those in Europe, need to increase to make US drug prices lower, rebalancing costs as CEO David Ricks recently advocated.

Lilly CEO Ricks Advocates Rebalancing Drug Pricing Between US And Europe

 
• By Mandy Jackson

As President Trump focuses on “most favored nation” pricing to bring down US drug costs, CEO David Ricks used Lilly’s Q2 earnings call to advocate for a slow approach to reducing the difference between US and EU drug prices.

Pharma Is Cooperating With Trump On Direct Sale To Consumers, Bourla Says

 
• By Jessica Merrill

Pfizer is in active discussions with Trump on MFN pricing and collaborating with peers on direct sales as an approach to lower drug prices, CEO Bourla said.

Most Favored Nation Pricing: Trump Ups Pressure On Voluntary Action, Clarifies Demands

 
• By Sarah Karlin-Smith

The new 60-day deadline for striking a deal with the drug industry underscores the challenges the Administration may be having in developing non-voluntary policies to achieve MFN pricing in the US.

More from Scrip

Deal Watch: Lilly Teams With GPCR-Focused Superluminal In Cardiometabolic Disease

 
• By Joseph Haas

Plus deals involving Basilea/Venatorx, CorMedix/Melinta, SERB/Y-mAbs, XOMA/Lava, XOMA/Hillevax, MaxCyte/Adicet/Anocca and Bausch Health/DURECT.

Lilly Begins Rebalancing US/Ex-US Drug Costs By Raising Prices In Europe

 
• By Mandy Jackson

Lilly said prices governments pay in developed countries, including those in Europe, need to increase to make US drug prices lower, rebalancing costs as CEO David Ricks recently advocated.

Schrödinger Drops CDC7 Inhibitor SGR-2921 After Two Patient Deaths

 
• By Alaric DeArment

The drug is one of multiple candidates in the class that have been pulled from development, though it is not the company’s lead candidate.